CCR8 is a member of the chemokine receptor family and functions as a G-protein coupled receptor. Extensive research has revealed that CCR8 exhibits specific expression on regulatory T cells (Treg) infiltrating tumors, as well as on Th2 cells and tumor cells.
The monoclonal antibody 1K17044-hIgG1, currently under development as an anti-CCR8 therapeutic, has demonstrated the capacity to induce discernible depletion of CCR8+ Treg cells in human tumor explants. This CCR8+ Treg depletion has translated into robust antitumor activity when administered as a standalone treatment and in combination with anti-PD-1 therapy in murine tumor models. These findings provide substantial support for further clinical exploration of CCR8 depletion, especially in conjunction with immune checkpoint blockade, as an innovative approach to cancer immunotherapy.